SMTNL1: A Potential Drug Target and Biomarker (G219537)

Target Name: SMTNL1

NCBI ID: G219537

SMTNL1

SMTNL1: A Potential Drug Target and Biomarker

Smoothelin-like protein 1 (SMTNL1) is a protein that has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. Its unique structure and function have made it an attractive target for researchers to investigate, and its potential as a drug or biomarker has gained significant interest in the scientific community.

SMTNL1 is a transmembrane protein that is expressed in various tissues and cells in the body. Its primary function is to regulate the actinin cytoskeleton, which is a complex network of filaments that provides structural support to cells and plays a crucial role in their mechanical properties. This protein helps to regulate the actinin cytoskeleton by interacting with the cytoskeleton-associated protein N-cadherin.

SMTNL1 has been shown to play a significant role in various physiological processes in the body, including cell division, tissue repair, and cell signaling. Its role in these processes has made it a potential drug target, as drugs that target SMTNL1 may have therapeutic benefits for diseases that are characterized by abnormal cell division, repair, or signaling.

SMTNL1 has also been shown to be involved in the development and progression of certain neurodegenerative disorders, such as Alzheimer's disease and Parkinson's disease. These disorders are characterized by the progressive loss of brain cells and the development of neurofibrillary tangles, which are thought to contribute to the symptoms of these disorders.

SMTNL1 has also been shown to be involved in the regulation of immune responses, which is an important function for many diseases, including cancer. In particular, studies have shown that SMTNL1 helps to regulate the development of immune cells that are involved in cancer, and that its levels are regulated by the immune response.

In addition to its potential as a drug target, SMTNL1 has also been shown to be a potential biomarker for various diseases. Its expression has been shown to be elevated in various tissues and cells in response to various stimuli, including cancer, neurodegenerative disorders, and autoimmune diseases. This suggests that SMTNL1 may be a useful biomarker for these diseases, and that its levels may be used to diagnose and monitor these conditions.

SMTNL1 has also been shown to have a unique structure that makes it an attractive target for drugs that are designed to disrupt its function. Studies have shown that SMTNL1 is able to interact with a variety of small molecules, including drugs that are used to disrupt its function. This suggests that SMTNL1 may be a useful target for drugs that are designed to disrupt its function and are being developed as potential therapeutic drugs.

In conclusion, SMTNL1 is a protein that has been identified as a potential drug target and biomarker for a variety of diseases. Its unique structure and function have made it an attractive target for researchers to investigate, and its potential as a drug or biomarker has gained significant interest in the scientific community. Further research is needed to fully understand the role of SMTNL1 in various physiological processes and to develop effective drugs or biomarkers that can disrupt its function.

Protein Name: Smoothelin Like 1

Functions: Plays a role in the regulation of contractile properties of both striated and smooth muscles. When unphosphorylated, may inhibit myosin dephosphorylation. Phosphorylation at Ser-299 reduces this inhibitory activity (By similarity)

The "SMTNL1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SMTNL1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets